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ABSTRACT
The spectrum of reimbursed molecular targeted agents for patients with metastatic colorectal cancer has been 
increased in Poland since July 2017. Following the Ministry of Health initiative, a team with the National Consultant 
in Clinical Oncology has prepared a new form of drug program. FOLFIRI combined with cetuximab or bevacizumab 
in the first line and aflibercept in the second line of treatment are now available as therapeutic options. In addition, 
by changing the eligibility criteria, the population of patients eligible for monotherapy with anti-EGFR antibody 
used in the third line was increased. Unfortunately, due to the fact that the manufacturers did not make the ap-
propriate refund requests, not all the assumptions were taken into account in the current form of the program. 
For example, panitumumab plus FOLFOX chemotherapy in the first line is still not reimbursed, and bevacizumab 
therapy should not be restricted to patients with RAS mutations. Despite this, the new program for treating patients 
with advanced colorectal cancer actually brings us closer to treatment standards in other countries and facilitates 
compliance with current medical knowledge.
Key words: colorectal cancer, palliative systemic treatment
Oncol Clin Pract 2017; 13, 4: 156–160
Introduction
Colorectal cancer is the second most common cancer 
in Poland and for decades it has been characterised by 
a growing trend of incidence. According to the National 
Cancer Registry in 2014, approximately 18 000 new cases 
were diagnosed (second place in women and third in 
men) and 11 500 deaths were registered (third place in 
women and secondin men) [1]. It is estimated that in at 
least one in five people, distant metastases are present at 
the time of the diagnosis. Also, among patients treated 
radically there is a significant risk of recurrence of the 
disease — it is more pronounced with more advanced 
primary process. Annually, the number of patients with 
non-operative locally advanced or metastatic colorectal 
cancer is approximately the same as the number of 
deaths caused by this disease.
Standard management of patients with a good 
performance status ineligible for radical treatment 
(metastasectomy) is a systemic palliative treatment [2, 
3]. The use of cytostatics and molecular-targeted drugs 
has significantly increased life expectancy. Today the 
median overall survival (mOS) of patients participating 
in phase III clinical trials exceeds 30 months. Cytotoxic 
drugs of proven efficacy in this indication (fluoropy-
rimidines, oxaliplatin, irinotecan) have long been re-
imbursed from public funds in Poland. Restrictions 
on the use of chemotherapy arise only from clinical 
considerations: performance status, functional capac-
ity, risk of treatment-related toxicity, or patient prefer-
ences. Molecularly-directed drugs, both anti-EGFR 
and anti-angiogenic agents, are reimbursed to a limited 
extent by the Ministry of Health drug programs. This is 
due to the high cost of next-generation therapy, and it 
is aimed at reducing the treated population to patients 
who have the greatest chance of obtaining the expected 
benefit on the basis of clinical trial data.
From 1 July 2017 a new program has been introduced 
in the treatment of patients with advanced colorectal 
cancer (Fig. 1) [4]. It allows wider access to biological 
therapies, and consequently leads to a change in the 
current strategy for the first-, second-, and third-line 
of palliative systemic treatment. It is worth mention-
ing that the initiative to change the shape of the drug 
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Figure 1. Treatment program for patients with metastatic colorectal cancer, applicable from 1 July 2017, including planned additions
program came from the Department of Drug Policy and 
Pharmacy of the Ministry of Health, and the new provi-
sions were proposed by a team with the participation 
of National Consultant in Clinical Oncology. Unfortu-
nately, due to formal reasons (no refund applications 
submitted in accordance with the program’s provisions), 
its present shape only partially corresponds to the origi-
nal assumptions.
The aim of this work is to shift new treatment options 
together with the reasons for their introduction and an 
indication of where the program adopted provisions 
differ from those originally developed.
First line of palliative systemic 
treatment
The basis of systemic treatment of the first line is 
chemotherapy. Most commonly used is the combina-
tion of fluoropyrimidine with irinotecan or oxaliplatin. 
It allows 30–50% objective response to treatment, and 
median progressive-free survival (mPFS) of 7–9 months 
[5]. Monotherapy with fluorouracil or capecitabine is 
better tolerated but less effective, especially with regard 
to responses and mPFS. Responses are achieved in ap-
proximately 25% of patients, and mPFS has a value of 
about five months [6]. Fluoropyrimidine monotherapy 
is commonly used in patients with low performance 
status, the presence of comorbid conditions, or when, 
due to the expected toxicity, multidrug chemotherapy 
is abandoned. In order to improve the effectiveness of 
palliative treatment, molecular-targeted drugs are added 
to the cytostatics.
The new Ministry of Health program introduces the 
possibility of using cetuximab with FOLFIRI chemo-
therapy in the first-line of treatment [4]. This treatment, 
compared with chemotherapy used alone, in the popula-
tion of patients with wild-type RAS genes, increases the 
rate of responses (66% vs. 39%, p < 0.001) and prolongs 
OS (median 28.4 vs. 20.2 months, HR = 0.69; 0.54–0.88; 
p = 0.0024). The disadvantage of combination therapy is 
the higher incidence of side effects, especially skin toxic-
ity. In the CRYSTAL study patients receiving cetuximab 
were observed more frequently to have severe skin rash 
(16% vs. 0%), diarrhoea (16% vs. 11%), neutropenia 
(28% vs. 25%), and hypersensitivity during infusion 
(2.3% vs. 0%) [7].
The novelty compared to the previous provisions is 
the obligation to exclude V600E mutation in the BRAF 
gene when qualifying for treatment with anti-EGFR 
drugs. The incidence of this mutation is 5–10%. This 
limitation is a result of two meta-analyses evaluating the 
predictive value of this mutation. In the first of them, 
on the basis of 463 carriers of the mutation BRAF gene 
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involved in 10 II- and III-phase trials, it was shown that 
cetuximab and panitumumab had no effect on the OS in 
this population (hazard ratio = 0.91; 95% CI 0.62–1.34, 
p = 0.63), PFS (HR = 0.88, 95% CI 0.67–1.14, p = 0.33) 
or response rate (HR = 1.31; 95% CI 0.83–2.08, 
p = 0.25) [8]. The second meta-analysis of 351 patients 
also showed no effect of anti-EGFR antibodies on the 
prognosis. Interpretation of this publication hinders 
the lack of significant difference between the results 
obtained in the population with wild-type and mutated 
BRAF (p = 0.43) [9].
A new therapeutic option available from July 1 this 
year is the combination of FOLFIRI regimen with 
bevacizumab in first-line treatment [4]. According to 
the program the following are eligible: patients with 
KRAS or NRAS activating mutations who have previously 
received adjuvant chemotherapy containing oxaliplatin. 
The value of bevacizumab in the first line of treatment 
raises some doubts. However, a meta-analysis of the first 
line of treatment, published in 2012, showed a prolon-
gation of OS following the addition of bevacizumab to 
irinotecan-containing chemotherapy (HR = 0.78, 95% 
CI 0.68–0.89, p = 0.0002) [10]. It is worth noting that 
the combination of oxaliplatin with anti-VEGF antibody 
did not improve the prognosis. Only two contradictory 
studies are included in the analysis of irinotecan. Decisive 
were results from Hurwitz et al. [11], who found that 
the addition of bevacizumab to the IFL chemotherapy 
was associated with an increase in mOS of almost five 
months (20.3 vs. 15.6 months, HR = 0.66; p < 0.001). 
In patients receiving bevacizumab, the following adverse 
avents were more frequently reported: hypertension 
(22.4% vs. 8.3%), proteinuria (26.5% vs. 21.7%), and 
thromboembolic complications (19.4% vs. 16.2%). The 
FOLFIRI scheme included in the Ministry of Health 
program is more effective and less toxic than IFL. Fur-
thermore, the combination of FOLFIRI or bevacizumab 
received approximately 27% of the patients participating 
in the CALGB/SWOG 80405 study, which demonstrated 
similar efficacy of the combination of chemotherapy with 
bevacizumab as with cetuximab. However, the small 
size of the analysed group makes it impossible to draw 
conclusions [12].
It should be pointed out that reducing the population 
of patients who may receive bevacizumab only to RAS 
gene mutation carriers has no rationale. On the contrary, 
data are available suggesting that the lack of KRAS muta-
tions may be a weak favourable predictor for anti-VEGF 
antibody therapy. A meta-analysis by Petrelli et al. [13] 
published in 2013 with the data from 2266 patients (46% 
were carriers of the mutation KRAS), indicated that 
bevacizumab combined with chemotherapy in patients 
with wild type of KRAS gene, as compared to the carriers 
of the mutation, increases the OS (HR = 0.65; 95% CI 
0.46–0.92; p = 0.01), PFS (HR = 0.85, 95% CI 0.74–0.98, 
p = 0.02) and increases the response rate (55% vs. 48%, 
OR 1.42, p = 0.02). Subsequent meta-analyses provided 
similar results [14, 15].
The original program design did not include the 
presence of activating mutation in KRAS and NRAS. 
The manufacturer of bevacizumab is responsible for the 
introduction of this criterion (a reimbursement applica-
tion for such a population was made several years ago).
Another significant requirement for bevacizumab 
combined with FOLFIRI is the prior use of adjuvant 
chemotherapy with oxaliplatin. It is worth explaining 
that the reason was to allow the use of bevacizumab in 
those patients currently unable to receive this antibody 
in the second line of treatment. Both in the previous and 
the current drug program, prior oxaliplatin therapy is 
the exclusive criterion for application of bevacizumab 
with FOLFOX regimen in the second-line treatment. 
Currently, depending on whether or not patients receive 
oxaliplatin-containing adjuvant treatment, they may 
receive an anti-VEGF antibody in the first or second 
line of treatment.
The most common BRAF V600E mutation is a rec-
ognised unfavourable prognostic factor. The median 
overall survival in BRAF mutation carriers may be up to 
three times lower compared to patients with a wild-type 
gene (10.4 vs. 34.7 months, p < 0.001) [16]. BRAF mu-
tations do not coexist with KRAS mutations [17]. This 
means that the introduction by the manufacturer of the 
criterion of presence of RAS mutation as a condition of 
bevacizumab therapy essentially prevents the use of this 
drug in the first line in patients with BRAF mutations.
An attempt to improve treatment outcomes in pa-
tients with the BRAF mutation is the addition of bevaci-
zumab to FOLFOXIRI regimen. The results of TRIBE 
study suggest that patients with BRAF mutations may 
benefit from such a procedure, but the limitations of this 
analysis are very small in the study population (28 carri-
ers of the BRAF mutation) [18]. The initial design of the 
program was — despite the sketchy clinical data pointing 
to the merits of such a procedure — the possibility of 
using FOLFOXIRI chemotherapy with bevacizumab in 
patients with BRAF mutations. However, this requires 
the manufacturer to submit the appropriate reimburse-
ment request.
An important gap in the new drug program is the lack 
of first-line chemotherapy with FOLFOX and panitu-
mumab due to the fact that the manufacturer failed to 
file a refund claim. Based on the PRIME study analysis 
it was demonstrated that the combination leads to an im-
proved prognosis of patients with RAS wild type genes. It 
was shown that mOS were 26.0 and 20.2 months, respec-
tively (HR = 0.78; 95% CI 0.62–0.99; p = 0.04), whereas 
mPFS medians 10.1 and 7.9 months (HR = 0.72; 95% 
CI 0.58–0.90; p = 0.004) [19]. The original design of the 
program assumed such an opportunity.
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Second line of palliative systemic 
treatment
The cytostatics used in the first line of treatment 
determine the choice of the second line. The efficacy of 
FOLFIRI, FOLFOX, or XELOX regimens are compa-
rable. Irinotecan monotherapy is used in patients with 
low performance status or with contraindications to 
the use of fluorouracil. The addition of anti-angiogenic 
drugs improves outcome.
In Poland, the public payer has financed bevaci-
zumab with FOLFOX4 chemotherapy in the second 
line since 2012 [4]. Qualification criteria and exclusions 
from the program have not changed. Treatment may 
be used in patients who have not previously received 
oxaliplatin-containing regimen. This record is a du-
plication of the inclusion criterion for the third-phase 
study that demonstrated the value of the anti-VEGF 
antibody. Bevacizumab added to second-line chemo-
therapy FOLFOX4 increases mOS by two months 
(12.9 vs. 10.8 months, HR = 0.75, p = 0.0011), mPFS by 
2.5 months (7.3 vs. 4.7 months, HR = 0.61, p = 0.0001), 
and the response rate (23% vs. 9%, p = 0.0001) [20].
The new program introduces the reimbursement of 
aflibercept plus FOLFIRI chemotherapy in second-line 
treatment [4]. Documentation of the ineffective pal-
liative treatment with fluoropyrimidine and oxalipl-
atin is required. It should be emphasised that for the 
above-mentioned reasons, in the current drug program 
there is no first-line combinations of panitumumab with 
FOLFOX in the first line. Consequently, aflibercept will 
be used in a very limited population (patients receiving 
oxaliplatin chemotherapy alone). Based on the results 
of the VELOUR study, the addition of aflibercept to 
FOLFIRI chemotherapy slightly improves OS (me-
dian 13.5 vs. 12.1, HR = 0.82, 95.34% CI 0.71–0.94; 
p = 0.0032), PFS (6.9 vs. 4.7; HR = 0.76; 95% CI 
0.66–0.87; p = 0.0001) and response rate (20% vs. 11%; 
p = 0.0001) [21]. Grade 3. or 4. adverse events were 
reported in 84% of patients receiving aflibercept and 
63% receiving placebo. Most common were neutropenia 
(37% vs. 30%), diarrhoea (19% vs. 8%), hypertension 
(19% vs. 2%), stomatitis (14% vs. 5%), and infectious 
complications (12% vs. 7%). Due to the severity of 
adverse events 27% of patients stopped treatment with 
aflibercept (in the control arm 12%).
The third line of palliative systemic 
treatment
In the third line of treatment, chemotherapy — aside 
from trifluridine/tipiracil — is of marginal importance. 
Molecular targeting drugs that improve the prognosis 
are panitumumab, cetuximab, and regorafenib. The 
value of anti-EGFR antibodies in patients with wild-type 
RAS and BRAF genes is not in doubt. In 2008, cetuximab 
was shown to improve OS (median 9.5 vs. 4.8 months, 
p < 0.001) and improve the quality of life when com-
pared to best supportive care [22]. On the other hand, 
the ASPECCT study confirmed the similar efficacy of 
panitumumab [23].
In Poland, both anti-EGFR antibodies are cur-
rently reimbursemed in the third line of treatment 
(cetuximab also in the first line). Anti-EGFR antibod-
ies used in monotherapy are available in individuals 
who have not received them before [4]. Analogously 
to first-line treatment, the need to exclude mutations 
in the BRAF gene was introduced. The required 
parameters of the blood morphology and renal and 
hepatic parameters were changed. The new criteria 
are platelet count ≥ 0.75 × 105/mm3, absolute neu-
trophil count ≥ 1000/mm3, haemoglobin concentra-
tion ≥ 8.0 g/dL, total bilirubin not exceeding three times 
the upper limit of normal (except for Gilbert syndrome), 
and creatinine concentration not exceeding twice the 
upper limit of normal. That gives an opportunity to use 
cetuximab or panitumumab also in patients in whom, as 
result of prior chemotherapy or advanced malignancy, 
deteriorated function of certain organs can be observed.
Summary
The new program for treating colorectal cancer 
— despite the fact that it significantly differs from the 
original proposal — extends the treatment options for 
patients with metastatic colorectal cancer according to 
current medical knowledge. There is the possibility to use 
cetuximab and bevacizumab in first-line treatment and 
aflibercept in the second line. Currently, a more rational 
and systematic approach to the clinical situation can be 
planned for systemic sequencing using both antiangiogenic 
and anti-EGFR antibodies. It is hoped that the recently 
submitted reimbursement application will allow to fund 
panitumumab in the first line, and that manufacturer of 
bevacizumab will soon submit the reimbursement request 
in line with the original design of the program
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